ARTICLE | Company News
MorphoSys, Boehringer Ingelheim deal
August 23, 2004 7:00 AM UTC
MOR will use its HuCal Gold technology to develop an antibody against an undisclosed cardiovascular disease target from Boehringer. Boehringer will be responsible for developing and marketing any res...